1/4/2012

Ossianix received a convertible promissory note from H. Lundbeck to help it develop biopharmaceutical agents for the central nervous system. Lundbeck has negotiation rights for certain medicines and technology resulting from the project. Separately, Lundbeck rolled out epilepsy treatment Onfi in the U.S.

Full Story:
Reuters

Related Summaries